Silo Pharma Inc. Initiates Key Safety Study for PTSD Drug SPC-15, Paving Way for First-in-Human Trials

Reuters

2025/05/14

Silo Pharma Inc. Initiates Key Safety Study for PTSD Drug SPC-15, Paving Way for First-in-Human Trials

Silo Pharma Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company, has announced a significant step forward in the development of its PTSD drug, SPC-15. The company has initiated a 7-day safety and toxicology study at Frontage Laboratories, a global contract research organization. This study, requested by the FDA, aims to gather crucial data to support Silo's investigational new drug $(IND.AU)$ application for SPC-15, an intranasal prophylactic treatment targeting the multi-billion-dollar PTSD market. The company remains on track to submit an FDA application this year, with plans to proceed to a first-in-human Phase 1 clinical trial upon approval. Silo has an exclusive global license from Columbia University for the development and commercialization of SPC-15.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9451016-en) on May 14, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2535213170"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535213170\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535213170?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-14 20:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535213170","market":"us","top_or_hot":-1,"title":"Silo Pharma Inc. Initiates Key Safety Study for PTSD Drug SPC-15, Paving Way for First-in-Human Trials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Silo Pharma Inc. Initiates Key Safety Study for PTSD Drug SPC-15, Paving Way for First-in-Human Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Silo Pharma Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company, has announced a significant step forward in the development of its PTSD drug, SPC-15. The company has initiated a 7-day safety and toxicology study at Frontage Laboratories, a global contract research organization. This study, requested by the FDA, aims to gather crucial data to support Silo's investigational new drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> application for SPC-15, an intranasal prophylactic treatment targeting the multi-billion-dollar PTSD market. The company remains on track to submit an FDA application this year, with plans to proceed to a first-in-human Phase 1 clinical trial upon approval. Silo has an exclusive global license from Columbia University for the development and commercialization of SPC-15.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9451016-en) on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Silo Pharma Inc. Initiates Key Safety Study for PTSD Drug SPC-15, Paving Way for First-in-Human Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSilo Pharma Inc. Initiates Key Safety Study for PTSD Drug SPC-15, Paving Way for First-in-Human Trials\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-14 20:40</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Silo Pharma Inc. Initiates Key Safety Study for PTSD Drug SPC-15, Paving Way for First-in-Human Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Silo Pharma Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company, has announced a significant step forward in the development of its PTSD drug, SPC-15. The company has initiated a 7-day safety and toxicology study at Frontage Laboratories, a global contract research organization. This study, requested by the FDA, aims to gather crucial data to support Silo's investigational new drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> application for SPC-15, an intranasal prophylactic treatment targeting the multi-billion-dollar PTSD market. The company remains on track to submit an FDA application this year, with plans to proceed to a first-in-human Phase 1 clinical trial upon approval. Silo has an exclusive global license from Columbia University for the development and commercialization of SPC-15.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9451016-en) on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2095319765.USD","symbol_name":"Natixis Thematics Subscription Economy R/A USD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL8FlPgQ:1","article_id":"2535213170","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535213170","pubTimestamp":1747226412,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Silo Pharma Inc. , a developmental stage biopharmaceutical company, has announced a significant step forward in the development of its PTSD drug, SPC-15. The company has initiated a 7-day safety and toxicology study at Frontage Laboratories, a global contract research organization. This study, requested by the FDA, aims to gather crucial data to support Silo's investigational new drug  application for SPC-15, an intranasal prophylactic treatment targeting the multi-billion-dollar PTSD market. The company remains on track to submit an FDA application this year, with plans to proceed to a first-in-human Phase 1 clinical trial upon approval. Silo has an exclusive global license from Columbia University for the development and commercialization of SPC-15.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shoul","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300347":"泰格医药","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SILO":"SILO PHARMA INC.","BK4585":"ETF&股票定投概念","BK0174":"增持","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4139":"生物科技","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK0216":"研究试验","NDAQ":"纳斯达克OMX交易所","BK4588":"碎股","BK4112":"金融交易所和数据","LU1146622755.USD":"安本中国A股股票基金A Acc","BK4202":"服装、服饰与奢侈品","BK0077":"质押式回购","BK0028":"国家队","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC"},"translate_title":"Silo Pharma Inc.启动PTSD药物SPC-15的关键安全性研究，为首次人体试验铺平道路","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300347":0.9,"SILO":0.9,"NDAQ":0.9},"content_text":"Silo Pharma Inc. Initiates Key Safety Study for PTSD Drug SPC-15, Paving Way for First-in-Human Trials\n    \n\n        Silo Pharma Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company, has announced a significant step forward in the development of its PTSD drug, SPC-15. The company has initiated a 7-day safety and toxicology study at Frontage Laboratories, a global contract research organization. This study, requested by the FDA, aims to gather crucial data to support Silo's investigational new drug $(IND.AU)$ application for SPC-15, an intranasal prophylactic treatment targeting the multi-billion-dollar PTSD market. The company remains on track to submit an FDA application this year, with plans to proceed to a first-in-human Phase 1 clinical trial upon approval. Silo has an exclusive global license from Columbia University for the development and commercialization of SPC-15.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9451016-en) on May 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}